EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

[203/212Pb]Pb-VMT-α-NET as a novel theranostic agent for targeted alpha radiotherapy—first clinical experience

Enrico Michler iD, David Kästner, Marc Pretze, Holger Hartmann, Robert Freudenberg, Michael K Schultz, Ralph A Bundschuh, Jörg Kotzerke, Claudia Brogsitter

European Journal of Nuclear Medicine and Molecular Imaging · 2025

DOI: 10.1007/s00259-025-07269-0 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2025. Verfasst von Enrico Michler und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, 01307, Dresden, Germany. en…. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Lead Radioisotopes, Alpha Particles, Theranostic Nanomedicine. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Carl Gustav Carus Dresden an der Technischen Universität Dresden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

203/212 Pb is a promising theranostic isotope pair for targeted alpha therapy (TAT) of neuroendocrine tumors (NET). VMT-α-NET is a novel SSTR2 targeting peptide that can be labeled with both isotopes. The aim of this work was to perform first clinical investigations of [ 203/212 Pb]Pb-VMT-α-NET regarding imaging, biokinetics, tolerability and response.

Methods

12 patients (9 m/3 w; mean age 71, range 60–84) with progressive metastatic GEP-NET grade 1–3 received diagnostic imaging with [ 203 Pb]Pb-VMT-α-NET (4.9 MBq/kg bw) up to 24 h p.i. (whole body & SPECT/CT) and, if eligible, a single dose of [ 212 Pb]Pb-VMT-α-NET therapy (1.2 MBq/kg bw) after exhaustion of all current therapies (including [ 177 Lu]Lu- & [ 225 Ac]Ac-DOTATATE), and post-treatment imaging with [ 212 Pb]Pb-VMT-α-NET up to 24 h p.i. (whole body & SPECT/CT). Clinical and laboratory parameters were monitored. A visual and quantitative comparison was made with [ 68 Ga]Ga-DOTATATE PET scans before and 3 months after therapy.

Results

No high-grade adverse effects were observed in all patients evaluated with [ 203 Pb]Pb-VMT-α-NET. All patients showed an initial high, but lesion-dependent heterogeneous intratumoral accumulation, comparable to [ 68 Ga]Ga-DOTATATE PET. Treatment with [ 212 Pb]Pb-VMT-α-NET was also well tolerated by all patients without high-grade or serious adverse side effects. Post-therapeutic PET scans and tumor marker controls showed stable findings in all patients up to 3 months after treatment.

Conclusion

Imaging with [ 203 Pb]Pb-VMT-α-NET followed by a single dose of [ 212 Pb]Pb-VMT-α-NET appears to be well tolerated with promising efficacy, even in a heterogenous and heavily pretreated patient population. Further studies are warranted to examine tolerability and efficacy over multiple treatment cycles in larger patient populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsLead RadioisotopesAlpha ParticlesTheranostic NanomedicineHumansAgedMiddle AgedMaleFemaleAged, 80 and overRadiopharmaceuticalsSingle Photon Emission Computed Tomography Computed Tomography

Stichwörter der Autor:innen

203Pb212PbNeuroendocrine tumorsTargeted alpha therapyTheranosticVMT-α-NET

Substanzen

Lead RadioisotopesLead-212Radiopharmaceuticals

Autor:innen und Institutionen

  • Department of Nuclear Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, 01307, Dresden, Germany. enrico.michler@uniklinikum-dresden.de.
  • Department of Nuclear Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstraße 74, 01307, Dresden, Germany.
  • Perspective Therapeutics Inc., Coralville, IA, USA.

ORCID-Profile: Enrico Michler

Förderung

  • Universitätsklinikum Carl Gustav Carus Dresden an der Technischen Universität Dresden

Zitieren

APA

Michler, E., Kästner, D., Pretze, M., Hartmann, H., Freudenberg, R., Schultz, M. K., Bundschuh, R. A., Kotzerke, J., & Brogsitter, C. (2025). [203/212Pb]Pb-VMT-α-NET as a novel theranostic agent for targeted alpha radiotherapy—first clinical experience. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-025-07269-0

Vancouver

Michler E, Kästner D, Pretze M, Hartmann H, Freudenberg R, Schultz MK, et al. [203/212Pb]Pb-VMT-α-NET as a novel theranostic agent for targeted alpha radiotherapy—first clinical experience. European Journal of Nuclear Medicine and Molecular Imaging. 2025. doi:10.1007/s00259-025-07269-0

BibTeX
@article{Michler2025,
  author = {Michler, Enrico and Kästner, David and Pretze, Marc and Hartmann, Holger and Freudenberg, Robert and Schultz, Michael K and Bundschuh, Ralph A and Kotzerke, Jörg and Brogsitter, Claudia},
  title = {[203/212Pb]Pb-VMT-α-NET as a novel theranostic agent for targeted alpha radiotherapy—first clinical experience},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2025},
  doi = {10.1007/s00259-025-07269-0}
}
Kostenlos starten →